JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

And now they’re launching it by way of their startup, ProFoldBio — one of nearly 70 startups that have emerged from UCSB’s New Venture Program — making the software available to other researchers in ...

A team of UC Santa Barbara engineering and molecular biology graduate students has developed software to accelerate the discovery process for therapies ...

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

High-throughput neutralisation tests could lead to a better understanding of the evolution of human influenza.

Download this handbook to learn more about the capabilities of mass photometry for evaluating antibody aggregation and ...

Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO ...

As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

Bruker now extends their complete biology approach to mouse research by announcing development of the CosMx Mouse Whole ...

Deal involving an antibody asset 'goes beyond a traditional licensing transaction', founder and CEO says China's Harbour ...

Amerigo Scientific reinforced its commitment to advancing the biomedical field by offering biomedical polymers tailored ...